[A13-05] Fidaxomicin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Last updated 15.04.2013
Commission awarded on 15.01.2013 by the Federal Joint Committee (G-BA).
Digestion, metabolism and hormones, Immune system and infections
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A20-25||Fidaxomicin (Clostridioides difficile infection) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A13-23||Addendum to Commission A13-05 (fidaxomicin)||Commission completed|